Anzeige
Mehr »
Login
Dienstag, 06.06.2023 Börsentäglich über 12.000 News von 686 internationalen Medien
Vollgas-Montag! NuGen Medical: Kurs hebt ab!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 881535 | ISIN: US75886F1075 | Ticker-Symbol: RGO
Tradegate
05.06.23
19:15 Uhr
700,50 Euro
0,00
0,00 %
1-Jahres-Chart
REGENERON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
REGENERON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
698,50702,5005.06.
698,00703,0005.06.

Aktuelle News zur REGENERON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoRegeneron Pharmaceuticals Unusual Options Activity For June 053
30.05.Regeneron Pharmaceuticals Unusual Options Activity6
26.05.Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study5
26.05.Regeneron Reveals Updated Data From Multiple Myeloma Study, Showing Response Rate Of 71%4
25.05.Regeneron Pharmaceuticals, Inc.: Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma17571% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO Benefit also...
► Artikel lesen
REGENERON PHARMACEUTICALS Aktie jetzt für 0€ handeln
25.05.Regeneron Pharmaceuticals, Inc.: Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations2
25.05.Regeneron Pharmaceuticals Unusual Options Activity For May 252
24.05.Sanofi/Regeneron's Dupixent shows promise in chronic obstructive pulmonary disease5
22.05.Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today2
22.05.Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained4
22.05.Sanofi, Regeneron flesh out COPD data with Dupixent6
21.05.Regeneron Pharmaceuticals, Inc.: Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine4
19.05.Regeneron (REGN) Faces Challenges as Eylea Sales Decline5
19.05.Regeneron Pharmaceuticals, Inc.: High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 20235
19.05.Samsung Biologics Faced with Patent Lawsuit from Regeneron in US6
18.05.SCOTUS hands win to Sanofi, Regeneron in long-running PCSK9 feud with Amgen2
18.05.Regeneron Pharmaceuticals, Inc.: Regeneron Announces Investor Conference Presentations1
18.05.Regeneron Pharmaceuticals, Inc.: Regeneron Applauds Supreme Court's Unanimous Opinion Striking Down Amgen's PCSK9 Patent Claims and Supporting Scientific Innovation344Decision ends nearly decade-long patent dispute related to Regeneron-invented Praluent® (alirocumab) TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)...
► Artikel lesen
18.05.Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron7
18.05.Breaking: SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen6
Seite:  Weiter >>
258 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1